يعرض 1 - 10 نتائج من 20 نتيجة بحث عن '"Goetze T. O."', وقت الاستعلام: 0.73s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Amato, G., Romano, G., Rodolico, V., Puleio, R., Calo, P. G., Di Buono, G., Cicero, L., Goetze, T. O., Agrusa, A.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36412894; info:eu-repo/semantics/altIdentifier/wos/WOS:000901110700001; volume:13; issue:4; numberofpages:13; journal:JOURNAL OF FUNCTIONAL BIOMATERIALS; https://hdl.handle.net/11584/354424Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85144882126

  2. 2
    مؤتمر

    المساهمون: Memorial Sloan Kettering Cancer Center, New York, NY

    العلاقة: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.4006Test; O'Reilly EM, Melisi D, Macarulla T, Roberto A, Cid P, Chandana SR, et al. Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000831.; http://hdl.handle.net/10541/626639Test; Journal of Clinical Oncology

  3. 3
    دورية أكاديمية

    المساهمون: David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

    العلاقة: https://doi.org/10.1016/s0140-6736Test(23)01366-1; Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Sep 11. PubMed PMID: 37708904. Epub 2023/09/15. eng.; http://hdl.handle.net/10541/626562Test; Lancet

  4. 4
    دورية أكاديمية
  5. 5
  6. 6
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    مصطلحات موضوعية: ddc:no

    العلاقة: Al-Batran, S-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G. M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U. S., Pauligk, C., Goetze, T. O. and Homann, N. (2020). Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Ann. Oncol., 31. S. S901 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية